Benralizamab, new treatment effective for attacks of asthma and COPD: Study Dr. Kamal Kant Kohli5 Dec 2024 8:45 PM ISTAn injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further...
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis Ruchika Sharma31 Oct 2024 1:45 PM ISTCambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult...
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis Dr. Kamal Kant Kohli20 Sept 2024 9:45 AM ISTAstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with...
CDSCO Panel grants AstraZeneca Pharma's proposal to include self-administration in package insert of Benralizumab Dr. Divya Colin26 Aug 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved drug major...
AstraZeneca Fasenra approved in China for severe eosinophilic asthma Ruchika Sharma23 Aug 2024 4:05 PM ISTCambridge: AstraZeneca's Fasenra (benralizumab) has been approved in China by the country's National Medical Products Association (NMPA) for the...
Tezepelumab novel therapeutic approach in uncontrolled severe non-type 2 asthma, case study suggests Medha Baranwal12 March 2024 3:00 AM ISTJapan: A recent case study published in Respirology Case Reports has shown that Tezepelumab could serve as a novel therapy for patients with...
Benralizumab as effective as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis: NEJM Dr. Kamal Kant Kohli26 Feb 2024 7:15 PM ISTResearchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic...
Benralizumab reduces inhaled corticosteroid usage and help in asthma control Aditi2 Jan 2024 11:00 PM ISTAsthma is a prevalent respiratory disease, affecting over 300 million people worldwide. Approximately 3-5% of asthma patients have severe disease,...
Major breakthrough-Benralizumab may independently control severe asthma without use of inhaled steroids Dr. Kamal Kant Kohli12 Dec 2023 9:45 AM ISTA landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids...
Benralizumab shows Promising in reducing COPD and asthma Exacerbations Jacinthlyn Sylvia3 Dec 2023 7:45 PM ISTA recent retrospective cohort study published in the Annals of Allergy, Asthma & Immunology unveiled the positive impact of benralizumab on...
AstraZeneca gets CDSCO Panel Nod to study asthma drug Benralizumab Dr. Divya Colin22 Sept 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
AstraZeneca Asthma drug Fasenra fails one main goal in study of chronic immune disease Ruchika Sharma28 Oct 2022 1:30 PM ISTUK: High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary...
